Name | 5-{2-Amino-4-oxo-3-[2-(trifluoromethyl)phenyl]-3,4-dihydro-6-quinazolinyl}-N-(2,4-difluorophenyl)-2-methoxy-3-pyridinesulfonamide |
---|---|
Synonyms |
3-Pyridinesulfonamide, 5-[2-amino-3,4-dihydro-4-oxo-3-[2-(trifluoromethyl)phenyl]-6-quinazolinyl]-N-(2,4-difluorophenyl)-2-methoxy-
5-{2-Amino-4-oxo-3-[2-(trifluoromethyl)phenyl]-3,4-dihydro-6-quinazolinyl}-N-(2,4-difluorophenyl)-2-methoxy-3-pyridinesulfonamide PI4KA inhibitor-F1 |
Description | GSK-F1 (Compound F1) is an orally active PI4KA inhibitor with pIC50 values of 8.0, 5.9, 5.8, 5.9, 5.9 and 6.4 against PI4KA, PI4KB, PI3KA, PI3KB, PI3KG and PI3KD, respectively. GSK-F1 can be used for HCV infection research[1]. |
---|---|
Related Catalog | |
Target |
PI4KA:8.0 (pIC50) PI4KB:5.9 (pIC50) PI3KA:5.8 (pIC50) PI3KB:5.9 (pIC50) PI3KG:5.9 (pIC50) PI3KD:6.4 (pIC50) |
References |
Density | 1.6±0.1 g/cm3 |
---|---|
Boiling Point | 744.3±70.0 °C at 760 mmHg |
Molecular Formula | C27H18F5N5O4S |
Molecular Weight | 603.52 |
Flash Point | 404.0±35.7 °C |
Exact Mass | 603.099976 |
LogP | 4.43 |
Vapour Pressure | 0.0±2.5 mmHg at 25°C |
Index of Refraction | 1.646 |
Storage condition | -20°C |
Hazard Codes | Xn |
---|